Liquid Biopsy Market 2020: Current Trends, Product Types, Application, Key Services, Advance Research, Segmentation and Opportunities, Forecast 2025

1
Global Liquid Biopsy Market

• Size 2018, by Application (Early Cancer
  Screening, Therapy Selection, Treatment
  Monitoring, Risk of Recurrence), Cancer Type
  (Lung Cancer, Breast Cancer, Colorectal Cancer,
  Prostate Cancer, Other Cancers) Circulating
  Biomarkers (Circulating Tumor Cells, Circulating
  Tumor DNA, Other Circulating Biomarkers), Region
  and Forecast 2019 to 2025

Single Use License US 4400
Request Sample
2
Global Liquid Biopsy Market To Grow From USD 812
Million In 2018 To USD 6,014 Million By 2025

• The global liquid biopsy market is anticipated to
  reach USD 6,014.2 million by 2025, growing at a
  CAGR of 33.4. Increasing cancer prevalence is a
  prime factor driving the global liquid biopsy
  market.
• Adroit Market Research report on global liquid
  biopsy market gives a holistic view of the market
  from 2017 to 2025, which includes factors such as
  market drivers, restraints, opportunities, and
  challenges. The market has been studied for
  historic year 2017, with the base year of
  estimation as 2018 and forecast from 2019 to
  2025. The report covers the current status and
  future traits of the market at global as well as
  country level along with the depiction of the
  industrys value chain. In addition, the study
  also assesses the market based on Porter's five
  forces analysis. Noticeable players serving in
  the global liquid biopsy market have also been
  studied in detail.
• Liquid biopsy is a minimally invasive technique
  that can identify molecular biomarkers in blood
  and other body fluids. Mainly used for cancer,
  liquid biopsies allow for detection and analysis
  of circulating tumour material (cells or DNA)
  shed into the blood from the primary tumour and
  from metastatic sites. Current clinical
  applications of liquid biopsy include patient
  stratification and therapy selection, monitoring
  treatment response and drug resistance, disease
  prognosis and detection of disease recurrence.
• The global liquid biopsy market has been
  segmented based on applications, cancer type, and
  circulating biomarker types. Based on
  applications, the market is broken down into
  early cancer screening, therapy selection,
  treatment monitoring and risk of recurrence.
  Early cancer screening is expected to account
  nearly 50 market share by 2025.

3
Global Liquid Biopsy Market To Grow From USD 812
Million In 2018 To USD 6,014 Million By 2025

• Asia Pacific is anticipated to be the fastest
  growing market through the forecast period. In
  this region rising income, increased
  urbanization, growing cancer cases, and
  governments focus on healthcare facilities is
  driving the liquid biopsy market. However, there
  are substantial barriers to liquid biopsy
  adoption. A number of assays intended on
  high-cost next generation sequencing technology
  are not reimbursed, obstructing market uptake.
  Moreover, cost of the procedure is facilitating
  access to a larger population in India, Japan and
  China, which depend heavily on out-of-pocket
  expenditure. Worldwide, in the race of active
  clinical trials in liquid biopsy East Asia ranks
  second, while China bangs the maximum number of
  trials. Therefore, it is advised that companies
  must design and develop randomized controlled
  trials and inclusion in guidelines to encourage
  broader acceptance and favorable payer coverage
  in Asia Pacific.
• Major players operating in the global liquid
  biopsy market are Biocept, Inc., Qiagen N.V.,
  Roche Diagnostics, Bio-Rad Laboratories, Inc.,
  Myriad Genetics, Inc., Menarini-Silicon
  Biosystems, Trovagene, Inc., Guardant Health,
  Inc. and Genomic Health, Inc. among others.
• Browse the complete report on _at_
  https//www.adroitmarketresearch.com/industry-repo
  rts/liquid-biopsy-market

4
Key segments of the global liquid biopsy market

• Application Overview, 2017-2025 (USD Million)
• Early cancer screening
• Therapy selection
• Treatment monitoring
• Risk of recurrence
• Cancer Type Overview, 2017-2025 (USD Million)
• Lung cancer
• Breast cancer
• Colorectal cancer
• Prostate cancer
• Other cancers
• Circulating Biomarker Overview, 2017-2025 (USD
  Million)
• Circulating tumor cells (CTCs)
• Circulating tumor DNA (ctDNA)
• Other circulating biomarkers

5
Key segments of the global liquid biopsy market

• Regional Overview, 2015-2025 (USD million) (Kilo
  tons)
• North America
• Europe
• Asia Pacific
• Central South America
• Middle East Africa
• Purchase a single user copy of the global liquid
  biopsy market report_at_ https//adroitmarketresearch
  .com/researchreport/purchase/1413

6
About Us

• Adroit Market Research is an India-based business
  analytics and consulting company. Our target
  audience is a wide range of corporations,
  manufacturing companies, product/technology
  development institutions and industry
  associations that require understanding of a
  markets size, key trends, participants and
  future outlook of an industry. We intend to
  become our clients knowledge partner and provide
  them with valuable market insights to help create
  opportunities that increase their revenues. We
  follow a code Explore, Learn and Transform. At
  our core, we are curious people who love to
  identify and understand industry patterns, create
  an insightful study around our findings and churn
  out money-making roadmaps. Our analysts have
  tracked high growth markets in chemicals
  materials, healthcare pharmaceuticals,
  semiconductor electronics, energy power, food
  retail, consumer goods, technology, and
  machinery equipment sectors across the world to
  identify new opportunities, potential customers,
  prepare go-to-market (GTM) strategies, identify
  segments for revenue growth for companies, and
  many more.

• US Headquarters3131 McKinney Ave Ste 600
  Dallas, TX 75204 ,U.S.A 

• Phone [phone]
• Email sales_at_adroitmarketresearch.com